CORONAVIRUS COVID-19 / SARS-CoV-2 Assays -- MEDICA - World Forum for Medicine

03.11.2020

DIA.PRO Diagnostic BioProbes Srl

CORONAVIRUS COVID-19 / SARS-CoV-2 Assays

COVID 19 DISEASE
The 2020 global diagnostic challenge

Dia.Pro offers Assay solutions, to assist scientific experts in addressing the COVID-19 Pandemic.
100% MADE IN ITALY
CE MARKED
ADAPTABLE ON THE MOST COMMON PROCESSING SYSTEMS

ELISA kits:

COVID 19 IgM
:
Monitoring of the immune response to COVID 19 in the early stage of the infection as an additional marker to PCR

COVID 19 IgA :
The IgA assay is recommended, in addition to IgG and IgM, to
(a) monitor the global immunological response of patients undergoing an acute infection and their follow up to full recovery
(b) specifically for testing patients with symptoms of the gastro enteric form of COVID 19 infection

COVID 19 IgG:  Monitoring of the immune response to COVID 19 Recommended in particular for testing
(a) infected individuals in follow up serological testing and when recovered from the infection, negative for COVID 19
PCR, to assure they developed IgG antibodies to the virus, confirming a full recovery from the infection
(b) health care workers at risk of covid 19 infection to verify whether or not they developed IgG antibodies to the virus
(c) individuals from normal population to study their acquired immune status against COVID 19 infection
(d) human antibodies donors for a preliminary screening of hyper immune sera as a possible candidate for an
immunotherapeutic approach to the treatment of the disease

COVID 19 IgG Confirmation: 
Module based Enzyme Immuno Assay for the Confirmatiogn typing of human samples screene d as positive for IgG The test is aimed to identify the specificity of antibodies to the major immunodominant COVID 19 antigens Nucleocapsid, Spike 1 and Spike 2

COVID 19 Spike 1 2 IgG: S
emi quantitative determination of IgG antibodies to COVID 19 Spike antigens Intended for testing
a) health care workers at risk of COVID 19 infection to verify whether or not they might be positive for potentially
neutralizing anti Spike IgG
b) normal population for epidemiology studies on presence of potential “ IgG to COVID 19 Spike antigens
c) PCR negative infected individuals successfully recovered from infection, to assure presence of potentially
neutralizing antibodies
d) human donors recovered from COVID 19 infection, positive for anti Spike IgG for the generation of hyperimmune plasma, as a possible immunotherapeutic approach to the disease e) vaccinated individuals to assure a reliable positive immunization with development of anti Spike IgG antibodies;

COVID 19 IgG/IgM Confirmation and Typing :
Module based Enzyme Immuno Assay for the Confirmation of samples positive for IgG and IgM antibodies to COVID 19 in first screening.


Real Time PCR kit

COVID 19 RNA: 
Specific qualitative detection of SARS CoV 2 in human samples by amplification of RdRp and N gene A simultaneous control of the extraction/amplification reaction through the RNA sequence of an endogenous Internal Control (IC)


Exhibitor Data Sheet